| 1. |
Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy[J]. Cancer Treat Rep, 1978, 62(3): 315-320.
|
| 2. |
Bommireddy T, Carrim ZI. To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity[J/OL]. BMJ Case Rep, 2016, 2016:bcr2015213431[2016-01-11]. http://europepmc.org/article/MED/26759403. DOI: 10.1136/bcr-2015-213431.
|
| 3. |
Nayfield SG, Gorin MB. Tamoxifen-associated eye disease: a review[J]. J Clin Oncol, 1996, 14(3): 1018-1026. DOI: 10.1200/JCO.1996.14.3.1018.
|
| 4. |
Doshi RR, Fortun JA, Kim BT, et al. Pseudocystic foveal cavitation in tamoxifen retinopathy[J]. Am J Ophthalmol, 2014, 157(6): 1291-1298. DOI: 10.1016/j.ajo.2014.02.046.
|
| 5. |
Cho KS, Yoon YH, Choi JA, et al. Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells[J]. Invest Ophthalmol Vis Sci, 2012, 53(9): 5344-5353. DOI: 10.1167/iovs.12-9827.
|
| 6. |
Kim LA, Amarnani D, Gnanaguru G, et al. Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms[J]. Invest Ophthalmol Vis Sci, 2014, 55(8): 4747-4758. DOI: 10.1167/iovs.13-13662.
|
| 7. |
Gualino V, Cohen SY, Delyfer MN, et al. Optical coherence tomography findings in tamoxifen retinopathy[J]. Am J Ophthalmol, 2005, 140(4): 757-758. DOI: 10.1016/j.ajo.2005.04.042.
|
| 8. |
Dyer MA, Cepko CL. Control of Müller glial cell proliferation and activation following retinal injury[J]. Nat Neurosci, 2000, 3(9): 873-880. DOI: 10.1038/78774.
|
| 9. |
Lee S, Kim HA, Yoon YH. OCT angiography findings of tamoxifen retinopathy: similarity with macular telangiectasia type 2[J]. Ophthalmol Retina, 2019, 3(8): 681-689. DOI: 10.1016/j.oret.2019.03.014.
|
| 10. |
Kovach JL, Isildak H, Sarraf D, et al. Crystalline retinopathy: unifying pathogenic pathways of disease[J]. Surv Ophthalmol, 2019, 64(1): 1-29. DOI: 10.1016/j.survophthal.2018.08.001.
|
| 11. |
Jack LS, Benson C, Sadiq MA, et al. Segmentation of retinal layers in sjögren-larsson syndrome[J]. Ophthalmology, 2015, 122(8): 1730-1732. DOI: 10.1016/j.ophtha.2015.02.003.
|
| 12. |
吉宇莹, 张雄泽, 李妙玲, 等. 2型黄斑毛细血管扩张症眼底及影像特征观察[J]. 中华眼底病杂志, 2016, 32(4): 382-386. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.009.Ji YY, Zhang XZ, Li ML, et al. Characteristics of fundus image in macular telangiectasia type 2[J]. Chin J Ocul Fundus Dis, 2016, 32(4): 382-386. DOI: 10.3760/cma.j.issn.1005-1015.2016.04.009.
|
| 13. |
Kim HA, Lee S, Eah KS, et al. Prevalence and risk factors of tamoxifen retinopathy[J]. Ophthalmology, 2020, 127(4): 555-557. DOI: 10.1016/j.ophtha.2019.10.038.
|
| 14. |
Davies C, Pan H, Godwin J, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816. DOI: 10.1016/S0140-6736(12)61963-1.
|
| 15. |
周慧颖, 叶俊杰, 陈有信. 双眼他莫昔芬视网膜病变一例[J]. 中华眼科杂志, 2017, 53(7): 548-550. DOI: 10.3760/cma.j.issn.0412-4081.2017.07.014.Zhou HY, Ye JJ, Chen YX. A case of bilateral tamoxifen retinopathy[J]. Chin J Ophlthalmol, 2017, 53(7): 548-550. DOI: 10.3760/cma.j.issn.0412-4081.2017.07.014.
|
